Nasdaq cyrx.

The US$31.00 analyst price target for CYRX is 33% less than our estimate of fair value. Does the April share price for Cryoport, Inc. (NASDAQ:CYRX) reflect what it's really worth? Today, we will ...

Nasdaq cyrx. Things To Know About Nasdaq cyrx.

Cryoport, Inc. (NASDAQ: CYRX) is redefining temperature-controlled supply chain support for the life sciences industry by continually broadening its platform of solutions and services, serving the ...Webull offers CYRX Ent Holdg (CYRX) historical stock prices, in-depth market analysis, NASDAQ: CYRX real-time stock quote data, in-depth charts, free CYRX options chain data, and a fully built financial calendar to help you invest smart.Get Our Latest Analysis on CYRX. Cryoport Trading Up 1.5 %. NASDAQ:CYRX opened at $9.66 on Thursday. The company has a current ratio of 14.54, a quick ratio of 13.82 and a debt-to-equity ratio of ...Cryoport, Inc. (Nasdaq: CYRX), is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the research ...

Balance Sheet. Stock analysis for CryoPort Inc (CYRX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and …CYRX CryoPort, Inc. Common Stock (CYRX) Add to Portfolio CYRX CYRX REAL TIME CYRX Real-Time Quotes 5D 1M 6M YTD 1Y 5Y MAX Last Five Real-Time Trades View …Shares of Cryoport, Inc. (NASDAQ:CYRX) were down 27% to $14.20 after the company announced lower than expected interim second-quarter earnings, FY23 guidance. First Wave BioPharma, Inc. ...

CYRX Related ETFs ; Total Stock Market ETF Vanguard ; SCHA, 0.02%, -1.47% ; Schwab U.S. Smallcap ETF ; VB, 0.01%, -0.67%.

Nov 10, 2023 · CryoPort Inc (NASDAQ:CYRX)’s Major holders CryoPort Inc insiders own 2.46% of total outstanding shares while institutional holders control 101.64%, with the float percentage being 104.20%. Brown Capital Management, LLC is the largest shareholder of the company, while 253 institutions own stock in it. NASHVILLE, Tenn., Feb. 15, 2023 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences industry focused on the pharmaceutical and cell and gene therapy markets, today announced that the Company will report …And CryoPort Inc (Symbol: CYRX) saw options trading volume of 2,021 contracts, representing approximately 202,100 underlying shares or approximately 49.5% of CYRX's average daily trading volume ...NASHVILLE, Tenn., Aug. 2, 2023 /PRNewswire/ -- CryoPort, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services for the fast growing cell and gene therapy industry, reproductive medicine and animal health industries, today announced that the Company will report financial results for the second …

16 hours ago. The Coca-Cola Company (NYSE:KO) Goes Ex-Dividend Soon. KO. 0.26%. Get the latest CYRX (CYRX) real-time quote, historical performance, charts, and other …

Jan 5, 2022 · Turning to the calls side of the option chain, the call contract at the $57.50 strike price has a current bid of $13.50. If an investor was to purchase shares of CYRX stock at the current price ...

Cryoport, Inc. (Nasdaq: CYRX) is redefining temperature-controlled supply chain support for the life sciences industry by continually broadening its platform of solutions and services, serving the ...NASHVILLE, Tenn. and TOKYO, Aug. 4, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in life sciences supply chain solutions, and MEDIPAL HOLDINGS CORPORATION (7459:JP), ("MEDIPAL") Japan's leading pharma wholesaler and distributor today announced a multi-year strategic business alliance …CryoPort, Inc. Common Stock (CYRX) · CYRX Latest After Hours Trades.Cryoport, Inc. (Nasdaq: CYRX), is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the research ...NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest...Cryoport (NASDAQ:CYRX) Third Quarter 2022 ResultsKey Financial Results. Revenue: US$60.5m (up 6.7% from 3Q 2021). Net loss: US$7.32m (loss narrowed by 14% from 3Q 2021). US$0.15 loss per share ...

Jul 31, 2023 · Cryoport, Inc. (NASDAQ:CYRX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 11 hedge fund portfolios held Cryoport, Inc. (NASDAQ:CYRX) at the end of first ... Dec 1, 2023 · 7 analysts have issued 12-month target prices for Cryoport's stock. Their CYRX share price targets range from $10.00 to $30.00. On average, they expect the company's stock price to reach $19.88 in the next twelve months. This suggests a possible upside of 41.8% from the stock's current price. View analysts price targets for CYRX or view top ... NASHVILLE, Tenn., Aug. 9, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell & gene therapy industry enabling the future of medicine for a new era of life sciences, today announced financial results for the second quarter (Q2 ...Cryoport, Inc. (Nasdaq: CYRX), is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the research ...16 oct 2020 ... Ver el gráfico CryoPort, Inc. en directo para realizar un seguimiento de los movimientos del precio de sus acciones.

CYRX Related ETFs ; Total Stock Market ETF Vanguard ; SCHA, 0.02%, -1.47% ; Schwab U.S. Smallcap ETF ; VB, 0.01%, -0.67%.

CYRX Overview Stock Screener Earnings Calendar Sectors Nasdaq | CYRX U.S.: Nasdaq Cryoport Inc. Watch list NEW Set a price target alert Open Last Updated: Nov 21, 2023 at 3:20 p.m. EST Real...May 25, 2023 · "Cryoport, Inc. (NASDAQ:CYRX): CYRX is a leading provider of cold chain logistics solutions to the life sciences industry. The company posted a 4Q22 revenue beat with 12% constant currency growth ... Cryoport, Inc. (NASDAQ:CYRX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 11 hedge fund portfolios held Cryoport, Inc. (NASDAQ:CYRX) at the end of first ...CYRX Stock 12 Months Forecast. $17.40. (18.37% Upside) Based on 5 Wall Street analysts offering 12 month price targets for CryoPort in the last 3 months. The average price target is $17.40 with a high forecast of $20.00 and a low forecast of $15.00. The average price target represents a 18.37% change from the last price of $14.70. NASHVILLE, Tenn., Feb. 8, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences ...May 11, 2022 · Currently procuring $180.2M for Fiscal 2021, $52.3M for 1Q2022 and projected to increase to $3B (estimated based on the $36.92B cell/gene therapy market that is growing at the 39.62% GAGR) $750M ... Cryoport, Inc. (Nasdaq: CYRX), is a global provider of innovative products and services to the fast-growing Cell & Gene Therapy industry - enabling the future of medicine for a new era of life ...

Cryoport, Inc. (Nasdaq: CYRX ), is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the ...

According to the issued ratings of 7 analysts in the last year, the consensus rating for Cryoport stock is Hold based on the current 5 hold ratings and 2 buy ratings for CYRX. The average twelve-month price prediction for Cryoport is $19.88 with a high price target of $30.00 and a low price target of $10.00. Learn more on CYRX's analyst rating ...

Cryoport, Inc. (Nasdaq: CYRX), is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the research, clinical and commercial spectrum. With over 40 strategic locations covering the Americas, EMEA (Europe, the Middle East and Africa) and APAC (Asia ...Cryoport, Inc. (Nasdaq: CYRX), is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the research ...Nov 23, 2023 · The stock of CryoPort Inc (NASDAQ: CYRX) has increased by 3.47 when compared to last closing price of 13.55. Despite this, the company has experienced a 5.41% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2023-11-09 that Cryoport, Inc. (NASDAQ:CYRX ) Q3 2023 Earnings Conference Call November 8, 2023 […] Cryoport, Inc. (Nasdaq: CYRX), headquartered in Nashville, TN, is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and ...Cryoport last released its earnings results on November 8th, 2023. The reported ($0.31) EPS for the quarter, hitting analysts' consensus estimates of ($0.31). The business earned $56.16 million during the quarter, compared to the consensus estimate of $55.24 million. Its quarterly revenue was down 7.1% on a year-over-year basis.With a Buy rating, UBS initiated coverage on CryoPort Inc (NASDAQ:CYRX). The price target seems to have been set at $84.00 for CryoPort. For the fourth quarter, CryoPort had an EPS of $0.26 ...Cryoport to Report Third Quarter 2021 Financial Results on November 4, 2021 NASHVILLE, Tennessee, October 28, 2021 - Cryoport, Inc. ("Cryoport" or the ... | May 21, 2023Cryoport Inc (NASDAQ:CYRX). 14.80. Delayed Data. As of Dec 01. +0.78 / +5.56%. Today's Change. 9.00. Today|||52-Week Range. 26.01. -14.70%. Year-to-Date. QuoteCryoport, Inc. (Nasdaq: CYRX) is redefining temperature-controlled supply chain support for the life sciences industry by continually broadening its platform of solutions, serving the Biopharma ...Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sonos Inc (Symbol: SONO), where a total of 11,073 contracts have traded so far ...

Follow. NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX). Such ...NASHVILLE, Tenn., Aug. 9, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell & gene therapy industry enabling the future of medicine for a new era of life sciences, today announced financial results for the second quarter (Q2 ...Cryoport, Inc. (Nasdaq: CYRX) is redefining temperature-controlled supply chain support for the life sciences industry by continually broadening its platform of solutions, serving the Biopharma ...NASHVILLE, Tenn., Nov. 8, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its ...Instagram:https://instagram. future trading vs forexflorida va mortgagesunshine profitsbest fha loan lenders Cryoport, Inc. (Nasdaq: CYRX), is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the research ...Cryoport, Inc. (Nasdaq: CYRX) is redefining temperature-controlled supply chain support for the life sciences industry by providing a platform of temperature-controlled solutions, serving the Biopharma, Reproductive Medicine, and Animal Health markets. lucid stock robinhoodnon qm loans near me Complete Cryoport Inc. stock information by Barron's. View real-time CYRX stock price and news, along with industry-best analysis. deere company stock Cryoport, Inc. (Nasdaq: CYRX), is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the research ...Cryoport, Inc. (Nasdaq: CYRX), is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the research ...